Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.

Lu, YSYSLuHsu, CCHsuLi, CCCCLiKuo, SHSHKuoKun-Huei, YehYehKun-HueiYang, CHCHYangHsu, CHCHHsuWu, CYCYWuCheng, AL.AL.Cheng2010-09-032018-07-092010-09-032018-07-092004-05http://ntur.lib.ntu.edu.tw//handle/246246/196312en-USPhase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.